Corporate Profile

Cortexyme is a biopharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is enrolling patients in a Phase 2/3 clinical trial of its lead small molecule in mild to moderate Alzheimer's disease.

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Investor Relations

News Releases

10 Jun '19
-- Event will be webcast, with Cortexyme presentation expected to start at 2:05 p.m. EDT tomorrow afternoon SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 10, 2019-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that Casey Lynch , the company’s chief executive officer, chairman, and

Recent Events

More events are coming soon.

Featured Reports

More information is coming soon.